Biotech's Plan B: Merge, Merge, Merge
- Biotech Charts Technology Recovery. Thurston, Charles W. // Global Finance;Sep2000, Vol. 14 Issue 9, p84
Discusses the recovery of biotechnology's initial public offering market as of September 2000. Remarks from Ronald B. Gies, vice president of corporate research at Stone & Youngberg; Rise in venture capital for biotechnology; Factors that lead to mergers and acquisitions in biotechnology industry.
- FIGs. // Investment Dealers' Digest;6/13/2005, Vol. 71 Issue 23, p38
Presents charts and a graph depicting the global underwriting volume as of June 6, 2005. Security type; Ranking of the top U.S. new issues bookrunners; Market share; Announcement of global target merger and acquisition advisers; Plans of JP Morgan and ABN Amro to enter the shipping futures...
- Shut Out of IPO Market, Trading at Low Levels? Reverse Mergers May Work, But Not for All: When a private company acquires a public shell, it's a cheap liquidity event. Lacey, Stephen // Investment Dealers' Digest;6/4/2001, Vol. 67 Issue 22, pN.PAG
Reports on an increase in reverse mergers due to closure of initial public offering markets and decline in prices of technology stocks. Advantages of reverse mergers for private companies; Features of reverse merger deals; Difficulties arising in the deals.
- Borzou Daragahi. // Money;Oct99, Vol. 28 Issue 10, p153
Offers the answer to a reader's question on Web sites that present all the details of mergers and acquisitions. Various sites that provide information on mergers and acquisitions; Various levels of detail provided by companies; How you can use the information to better predict stock performance.
- Transoma postpones IPO citing 'unfavorable' market conditions. // Cardiovascular Devices & Drugs;Feb2008, Vol. 14 Issue 2, p25
The article reports on the plan of Transoma Medical to postpone its initial public offering (IPO) due to unfavorable market conditions. The company has reported its IPO pricing in the $14 to $16 range. It first reported filing for the public offering in fall 2007. It said that the proceeds will...
- From the analyst's couch: The outlook for biotech exits. Grimaldi, Annette // Nature Biotechnology;Mar2014, Vol. 32 Issue 3, p227
The author discuses the performance of biopharmaceutical sector in the initial public offering (IPO) markets from 2008 to 2013. It informs the transaction value of mergers and acquisitions for public and private biopharmaceutical industry for 10.1 billion dollars as of January 31, 2018. It also...
- IPO Insight:Facebook Sets a Price Range and Hits the Road. CODY, TAMIKA // Mergers & Acquisitions Report;5/7/2012, Vol. 25 Issue 19, p10
The article reports on the move by social networking site Facebook Inc. to update the S-1 for its highly anticipated initial public offering (IPO) and set a price range of 28 to 35 U.S. dollars per share on May 3, 2012. Published reports confirmed that Facebook will debut its roadshow on May 7,...
- OctoPlus Shares Surge After Dr. Reddy's $36M Buyout Bid. Sheridan, Cormac // BioWorld Today;10/23/2012, Vol. 23 Issue 206, p2
The article reports on the 27.4 million euro-cash buyout offer accepted by OctoPlus NV from Dr. Reddy's Laboratories Ltd. The event has pushed OctoPlus share price up by 23 percent. Dr. Reddy's is now planning to proceed with a recommended public offer for all the outstanding shares of OctoPlus....
- Exchanges' megadeal sets stage for more. Strahler, Steven R. // Crain's Chicago Business;10/23/2006, Vol. 29 Issue 43, p1
The article presents information related to the merger of Chicago Mercantile Exchange and the Chicago Board of Trade. Stock of Chicago Mercantile has increased 14-times since a 2002 initial public offering to close at $490.18 a share. Craig Donohue, CEO of Chicago Mercantile, said that...